Literature DB >> 24844602

Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.

Milica Cerovic1, Vincenza Bagetta2, Valentina Pendolino2, Veronica Ghiglieri2, Stefania Fasano3, Ilaria Morella3, Neil Hardingham4, Andreas Heuer4, Alessandro Papale3, Francesca Marchisella3, Carmela Giampà2, Paolo Calabresi5, Barbara Picconi2, Riccardo Brambilla6.   

Abstract

BACKGROUND: Bidirectional long-term plasticity at the corticostriatal synapse has been proposed as a central cellular mechanism governing dopamine-mediated behavioral adaptations in the basal ganglia system. Balanced activity of medium spiny neurons (MSNs) in the direct and the indirect pathways is essential for normal striatal function. This balance is disrupted in Parkinson's disease and in l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (LID), a common motor complication of current pharmacotherapy of Parkinson's disease.
METHODS: Electrophysiological recordings were performed in mouse cortico-striatal slice preparation. Synaptic plasticity, such as long-term potentiation (LTP) and depotentiation, was investigated. Specific pharmacological inhibitors or genetic manipulations were used to modulate the Ras-extracellular signal-regulated kinase (Ras-ERK) pathway, a signal transduction cascade implicated in behavioral plasticity, and synaptic activity in different subpopulations of striatal neurons was measured.
RESULTS: We found that the Ras-ERK pathway, is not only essential for long-term potentiation induced with a high frequency stimulation protocol (HFS-LTP) in the dorsal striatum, but also for its reversal, synaptic depotentiation. Ablation of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a neuronal activator of Ras proteins, causes a specific loss of HFS-LTP in the medium spiny neurons in the direct pathway without affecting LTP in the indirect pathway. Analysis of LTP in animals with unilateral 6-hydroxydopamine lesions (6-OHDA) rendered dyskinetic with chronic L-DOPA treatment reveals a complex, Ras-GRF1 and pathway-independent, apparently stochastic involvement of ERK.
CONCLUSIONS: These data not only demonstrate a central role for Ras-ERK signaling in striatal LTP, depotentiation, and LTP restored after L-DOPA treatment but also disclose multifaceted synaptic adaptations occurring in response to dopaminergic denervation and pulsatile administration of L-DOPA.
Copyright © 2015 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Depotentiation; L-DOPA-induced dyskinesia; Long-term depression (LTD); Long-term potentiation (LTP); Ras-ERK signaling; Ras-GRF1; Striatum

Mesh:

Substances:

Year:  2014        PMID: 24844602     DOI: 10.1016/j.biopsych.2014.04.002

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  23 in total

Review 1.  Hyperkinetic disorders and loss of synaptic downscaling.

Authors:  Paolo Calabresi; Antonio Pisani; John Rothwell; Veronica Ghiglieri; Josè A Obeso; Barbara Picconi
Journal:  Nat Neurosci       Date:  2016-06-28       Impact factor: 24.884

Review 2.  Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?

Authors:  Paolo Calabresi; Veronica Ghiglieri; Petra Mazzocchetti; Ilenia Corbelli; Barbara Picconi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

Review 3.  Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.

Authors:  Barbara Picconi; Elvira De Leonibus; Paolo Calabresi
Journal:  J Neural Transm (Vienna)       Date:  2018-02-28       Impact factor: 3.575

4.  D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease.

Authors:  Irene Sebastianutto; Elise Goyet; Laura Andreoli; Joan Font-Ingles; David Moreno-Delgado; Nathalie Bouquier; Céline Jahannault-Talignani; Enora Moutin; Luisa Di Menna; Natallia Maslava; Jean-Philippe Pin; Laurent Fagni; Ferdinando Nicoletti; Fabrice Ango; M Angela Cenci; Julie Perroy
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 5.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

6.  Diverse Mechanisms Lead to Common Dysfunction of Striatal Cholinergic Interneurons in Distinct Genetic Mouse Models of Dystonia.

Authors:  Karen L Eskow Jaunarajs; Mariangela Scarduzio; Michelle E Ehrlich; Lori L McMahon; David G Standaert
Journal:  J Neurosci       Date:  2019-07-18       Impact factor: 6.167

7.  Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.

Authors:  Cristina Alcacer; Laura Andreoli; Irene Sebastianutto; Johan Jakobsson; Tim Fieblinger; Maria Angela Cenci
Journal:  J Clin Invest       Date:  2017-01-23       Impact factor: 14.808

8.  RASGRF1 in CRF cells controls the early adolescent female response to repeated stress.

Authors:  Shan-Xue Jin; David A Dickson; Jamie Maguire; Larry A Feig
Journal:  J Endocrinol       Date:  2020-06       Impact factor: 4.286

9.  M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Authors:  Weixing Shen; Joshua L Plotkin; Veronica Francardo; Wai Kin D Ko; Zhong Xie; Qin Li; Tim Fieblinger; Jürgen Wess; Richard R Neubig; Craig W Lindsley; P Jeffrey Conn; Paul Greengard; Erwan Bezard; M Angela Cenci; D James Surmeier
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

10.  Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.

Authors:  Sherri L Thiele; Betty Chen; Charlotte Lo; Tracey S Gertler; Ruth Warre; James D Surmeier; Jonathan M Brotchie; Joanne E Nash
Journal:  Neurobiol Dis       Date:  2014-08-27       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.